TCGA-A2-A3KD-01A-12R-A213-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 40
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_EARLY+0.410
- NOTCH_SIGNALING+0.340
- PROTEIN_SECRETION+0.340
- ESTROGEN_RESPONSE_LATE+0.320
- UV_RESPONSE_DN+0.320
- BILE_ACID_METABOLISM+0.250
- APICAL_SURFACE+0.240
- ANDROGEN_RESPONSE+0.210
- TGF_BETA_SIGNALING+0.210
- WNT_BETA_CATENIN_SIGNALING+0.210
Top 10 suppressed
- E2F_TARGETS-0.500
- INTERFERON_ALPHA_RESPONSE-0.490
- MYC_TARGETS_V1-0.440
- OXIDATIVE_PHOSPHORYLATION-0.430
- INTERFERON_GAMMA_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.340
- DNA_REPAIR-0.330
- G2M_CHECKPOINT-0.320
- MYC_TARGETS_V2-0.240
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | s0112281 | — | — | 0.810 |
| 2 | TCGA-AC-A2FG-01A-11R-A17B-07 | — | A | 0.789 |
| 3 | TCGA-97-7547-01A-11R-2039-07 | — | cohortA1 | 0.789 |
| 4 | MNG238 | — | — | 0.769 |
| 5 | TCGA-BH-A0DO-01B-11R-A12D-07 | — | A | 0.760 |
| 6 | TCGA-AR-A24W-01A-11R-A169-07 | — | A | 0.747 |
| 7 | TCGA-44-6146-01A-11R-1755-07 | — | cohortA1 | 0.746 |
| 8 | TCGA-OR-A5LL-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.745 |
| 9 | TCGA-E2-A1L6-01A-11R-A13Q-07 | — | A | 0.743 |
| 10 | TCGA-D8-A27P-01A-11R-A16F-07 | — | B | 0.741 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_EARLY | 0.410 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.340 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |